Skip to main content
Erschienen in: Strahlentherapie und Onkologie 1/2012

01.01.2012 | Original article

Survival of patients with head and neck cancer

Impact of physical status and comorbidities

verfasst von: F. Sadat, A. Wienke, J. Dunst, T. Kuhnt, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Prognostic factors (e.g., gender, tumor stage, and hypoxia) have an impact on survival in patients with head and neck cancer. Thus, the impact of physical status and comorbidities on treatment decision and survival were evaluated.

Patients and methods

A total of 169 primary, inoperable patients with squamous cell cancer of the head and neck were retrospectively investigated. Patients were treated with hyperfractionated accelerated radio(chemo)therapy (HARcT) or hypofractionated radio(chemo)therapy (HypoRcT). Depending on the individual patient’s situation (Karnofsky Performance Index, KPI), treatment for patients with a KPI of 80–100% was generally radiochemotherapy and for patients with a KPI ≤ 70% treatment was radiotherapy alone. In addition, all comorbidities were evaluated. Uni- and multivariate proportional hazards model were used, and overall survival (OS) was estimated by the Kaplan–Meier method.

Results

Treatment consisted of HARcT for 76 patients (45%), HART for 28 patients (17%), HypoRcT for 14 patients(8%), and HypoRT for 51 patients (30%). Of the patients, 107 patients (63%) presented with a KPI of 80–100%. OS (20%) was significantly better for patients with a KPI of 80–100%, while the OS for patients with a KPI ≤ 70% was 8% (p < 0.001). Good KPI, total irradiation dose (> 70 Gy), and chemotherapy were significant prognostic factors for better OS.

Conclusion

Our retrospective analysis shows that performance status with dependency on comorbidities was an independent risk factor for OS.
Literatur
1.
Zurück zum Zitat Bradley JD, Ieumwananonthachai N, Purdy JA et al (2002) Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52:49–57PubMedCrossRef Bradley JD, Ieumwananonthachai N, Purdy JA et al (2002) Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52:49–57PubMedCrossRef
2.
Zurück zum Zitat Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 23:1125–1135PubMedCrossRef Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 23:1125–1135PubMedCrossRef
3.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies. J Chronc Dis 40:373–383CrossRef Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies. J Chronc Dis 40:373–383CrossRef
4.
Zurück zum Zitat Cleary PD, Greenfield SG, Mulley AG et al (1991) Variation in length of stay and outcomes for six medical and surgical conditions in Massachusetts and California. JAMA 266:73–79PubMedCrossRef Cleary PD, Greenfield SG, Mulley AG et al (1991) Variation in length of stay and outcomes for six medical and surgical conditions in Massachusetts and California. JAMA 266:73–79PubMedCrossRef
5.
Zurück zum Zitat Dietl B, Marienhagen J, Schaefer C et al (2007) Survival with distant metastatic disease in head and neck cancer. A retrospective analysis. HNO 55:788–791CrossRef Dietl B, Marienhagen J, Schaefer C et al (2007) Survival with distant metastatic disease in head and neck cancer. A retrospective analysis. HNO 55:788–791CrossRef
6.
Zurück zum Zitat Dunst J, Stadler P, Becker A et al (2003) Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 179:521–526PubMedCrossRef Dunst J, Stadler P, Becker A et al (2003) Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 179:521–526PubMedCrossRef
7.
Zurück zum Zitat Fietkau R (2000) Tumor volume as a prognostic factor in the radiotherapy of carcinomas in the head-neck area. Strahlenther Onkol 176:382–383PubMedCrossRef Fietkau R (2000) Tumor volume as a prognostic factor in the radiotherapy of carcinomas in the head-neck area. Strahlenther Onkol 176:382–383PubMedCrossRef
8.
Zurück zum Zitat Gunn GB, Endres EJ, Parker B et al (2010) A phase I/II study of altered fractionated IMRT alone for intermediate T-stage oropharyngeal carcinoma. Strahlenther Onkol 186:489–495PubMedCrossRef Gunn GB, Endres EJ, Parker B et al (2010) A phase I/II study of altered fractionated IMRT alone for intermediate T-stage oropharyngeal carcinoma. Strahlenther Onkol 186:489–495PubMedCrossRef
9.
Zurück zum Zitat Hall SF, Rochon PA, Streiner DL et al (2002) Measuring comorbidity in patients with head and neck cancer. Laryngoscope 112:1988–1996PubMedCrossRef Hall SF, Rochon PA, Streiner DL et al (2002) Measuring comorbidity in patients with head and neck cancer. Laryngoscope 112:1988–1996PubMedCrossRef
10.
Zurück zum Zitat Jeremic B, Milicic B (2009) Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. Am J Clin Oncol 32:63–68 Jeremic B, Milicic B (2009) Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. Am J Clin Oncol 32:63–68
11.
Zurück zum Zitat Kaplan MH, Feinstein AR (1974) The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chronc Dis 27:387–404CrossRef Kaplan MH, Feinstein AR (1974) The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chronc Dis 27:387–404CrossRef
12.
Zurück zum Zitat Karnofsky DA, Abelmann WH, Craver LF et al (1948) The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1:634–656CrossRef Karnofsky DA, Abelmann WH, Craver LF et al (1948) The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1:634–656CrossRef
13.
Zurück zum Zitat Kuhnt T, Janich M, Götz U et al (2006) Presentation of a 3D conformal radiotherapy technique for head-and-neck tumors resulting in substantial protection of the parotid glands. Strahlenther Onkol 182:325–330PubMedCrossRef Kuhnt T, Janich M, Götz U et al (2006) Presentation of a 3D conformal radiotherapy technique for head-and-neck tumors resulting in substantial protection of the parotid glands. Strahlenther Onkol 182:325–330PubMedCrossRef
14.
Zurück zum Zitat Kuhnt T, Klockenbrink U, Knipping S et al (2011) Adjuvant low single dose cisplatin-based concurrent radiochemotherapy of oral cavity and oropharynx carcinoma: impact of extracapsular nodal spread on distant metastases. Strahlenther Onkol 187:292–299PubMedCrossRef Kuhnt T, Klockenbrink U, Knipping S et al (2011) Adjuvant low single dose cisplatin-based concurrent radiochemotherapy of oral cavity and oropharynx carcinoma: impact of extracapsular nodal spread on distant metastases. Strahlenther Onkol 187:292–299PubMedCrossRef
15.
Zurück zum Zitat Kuhnt T, Mueller AC, Pelz T et al (2005) Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy. J Cancer Res Clin Oncol 131:758–764PubMedCrossRef Kuhnt T, Mueller AC, Pelz T et al (2005) Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy. J Cancer Res Clin Oncol 131:758–764PubMedCrossRef
16.
Zurück zum Zitat Kreppel M, Drebber U, Eich HT et al (2011) Combined-modality treatment in advanced oral squamous cell carcinoma: primary surgery followed by adjuvant concomitant radiochemotherapy. Strahlenther Onkol 187:555–560PubMedCrossRef Kreppel M, Drebber U, Eich HT et al (2011) Combined-modality treatment in advanced oral squamous cell carcinoma: primary surgery followed by adjuvant concomitant radiochemotherapy. Strahlenther Onkol 187:555–560PubMedCrossRef
17.
Zurück zum Zitat Linn BS, Linn MW, Lee G (1968) Cumulative illness rating scale. J Am Geriatr Soc 5:622–626 Linn BS, Linn MW, Lee G (1968) Cumulative illness rating scale. J Am Geriatr Soc 5:622–626
18.
Zurück zum Zitat Paleri V, Wight RG, Silver CE et al (2010) Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol 46:712–719PubMedCrossRef Paleri V, Wight RG, Silver CE et al (2010) Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol 46:712–719PubMedCrossRef
19.
Zurück zum Zitat Rades D, Stoehr M, Meyners T et al (2008) Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer. Strahlenther Onkol 184:198–205PubMedCrossRef Rades D, Stoehr M, Meyners T et al (2008) Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer. Strahlenther Onkol 184:198–205PubMedCrossRef
20.
Zurück zum Zitat Ragin CC, Modugno F, Gollin SM et al (2007) The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 86:104–114PubMedCrossRef Ragin CC, Modugno F, Gollin SM et al (2007) The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 86:104–114PubMedCrossRef
21.
Zurück zum Zitat Robert Koch Institut (ed) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland (2010) Krebs in Deutschland 2005/2006. Häufigkeiten und Trends, 7. edition. Berlin Robert Koch Institut (ed) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland (2010) Krebs in Deutschland 2005/2006. Häufigkeiten und Trends, 7. edition. Berlin
22.
Zurück zum Zitat Rubin P, Constine LS, Fajardo LF et al (1995) RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 31:1041–1042PubMedCrossRef Rubin P, Constine LS, Fajardo LF et al (1995) RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 31:1041–1042PubMedCrossRef
23.
Zurück zum Zitat Sanabria A, Carvalho AL, Vartanian JG et al (2007) Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 14:1449–1457PubMedCrossRef Sanabria A, Carvalho AL, Vartanian JG et al (2007) Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 14:1449–1457PubMedCrossRef
24.
Zurück zum Zitat Schafer U, Micke O, Mueller SB et al (2003) Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 179:527–534PubMedCrossRef Schafer U, Micke O, Mueller SB et al (2003) Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 179:527–534PubMedCrossRef
25.
Zurück zum Zitat Steinmann D, Cerny B, Karstens JH et al (2009) Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis. Strahlenther Onkol 185:682–688PubMedCrossRef Steinmann D, Cerny B, Karstens JH et al (2009) Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis. Strahlenther Onkol 185:682–688PubMedCrossRef
26.
Zurück zum Zitat Studer G, Seifert B, Glanzmann C (2008) Prediction of distant metastasis in head neck cancer patients: implications for induction chemotherapy and pre-treatment staging? Strahlenther Onkol 184:580–585PubMedCrossRef Studer G, Seifert B, Glanzmann C (2008) Prediction of distant metastasis in head neck cancer patients: implications for induction chemotherapy and pre-treatment staging? Strahlenther Onkol 184:580–585PubMedCrossRef
27.
Zurück zum Zitat Tribius S, Kronemann S, Kilic Y et al (2009) Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck. Strahlenther Onkol 185:675–681PubMedCrossRef Tribius S, Kronemann S, Kilic Y et al (2009) Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck. Strahlenther Onkol 185:675–681PubMedCrossRef
28.
Zurück zum Zitat VonKorff M, Wagner EH, Saunders K (1992) A chronic disease score from automated pharmacy data. J Clin Epidemiol 45:197–203CrossRef VonKorff M, Wagner EH, Saunders K (1992) A chronic disease score from automated pharmacy data. J Clin Epidemiol 45:197–203CrossRef
29.
Zurück zum Zitat Wolff HA, Bosch J, Jung K, Overbeck T et al (2010) High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol 186:262–268PubMedCrossRef Wolff HA, Bosch J, Jung K, Overbeck T et al (2010) High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol 186:262–268PubMedCrossRef
30.
Zurück zum Zitat Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky Performance Status. Cancer 45:222–224CrossRef Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky Performance Status. Cancer 45:222–224CrossRef
31.
Zurück zum Zitat Zubrod CG, Schneiderman M, Frei E et al (1960) Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 11:7–33CrossRef Zubrod CG, Schneiderman M, Frei E et al (1960) Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 11:7–33CrossRef
Metadaten
Titel
Survival of patients with head and neck cancer
Impact of physical status and comorbidities
verfasst von
F. Sadat
A. Wienke
J. Dunst
T. Kuhnt, MD
Publikationsdatum
01.01.2012
Verlag
Urban and Vogel
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 1/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-011-0009-8

Weitere Artikel der Ausgabe 1/2012

Strahlentherapie und Onkologie 1/2012 Zur Ausgabe

Mitteilungen der Fachgesellschaften

Mitteilungen der Fachgesellschaften

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.